Skip Navigation


European Heart Journal Advance Access originally published online on June 13, 2008
European Heart Journal 2008 29(13):1595-1596; doi:10.1093/eurheartj/ehn068
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
29/13/1595    most recent
ehn068v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mukherjee, D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mukherjee, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Optimal treatment for in-stent restenosis after BMS—DES, coated balloon, or scalpel?

Debabrata Mukherjee*

Gill Heart Institute, University of Kentucky, Lexington, KY 40536-0200, USA

* Corresponding author. Tel: +1 859 323 5630, Fax: +1 859 323 6475. Email: Mukherjee@uky.edu

This editorial refers to ‘Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial’{dagger} by S.G. Ellis et al., on page 1625

Footnotes

The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

The first 10% of the full text of this article appears below.

The year 2007 saw a significant decrease in the usage of drug-eluting stents (DES)1 and a commensurate increase in the usage of bare metal stents (BMS) primarily because of concern about stent thrombosis with DES. As a result of increased use of BMS, we are likely to see more patients presenting with in-stent restenosis (ISR) after BMS, and determining the optimal treatment of these individuals becomes clinically relevant.

During the last decade, numerous modalities have been used to treat ISR after BMS, with only modest intermediate-term efficacy. These devices, including . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial
Stephen G. Ellis, Charles D. O'Shaughnessy, Steven L. Martin, Kenneth Kent, Thomas McGarry, Mark A. Turco, Dean J. Kereiakes, Jeffrey J. Popma, Mark Friedman, Joerg Koglin, Gregg W. Stone, and for the TAXUS V ISR Investigators
EHJ 2008 29: 1625-1634. [Abstract] [Full Text]